Skip to main content
Equibles

Dolly Vance

Analyst

Senior Advisor, Legal & Corporate Affairs

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Dolly Vance

Dolly Vance is recorded as Analyst at Senior Advisor, Legal & Corporate Affairs. Earlier roles on record: General Counsel at Rigel Pharmaceuticals Inc (RIGL) until October 11, 2022. Rigel Pharmaceuticals Inc reported in an 8-K filed October 11, 2022 that Dolly Vance retired as general counsel, executive vice president, corporate affairs, and corporate secretary, effective October 11, 2022. The proxy statement of Rigel Pharmaceuticals Inc reports total compensation of $1,194,583 for Dolly Vance in fiscal 2020, including a base salary of $524,890. Disclosed compensation is on record for 3 fiscal years. Dolly Vance has spoken on 10 earnings calls across 1 company, most recently for Rigel Pharmaceuticals Inc on August 2, 2022.

“On October 11, 2022, Dolly A. Vance provided notice of her retirement from her position as general counsel, executive vice president, corporate affairs, and corporate secretary of Rigel, effective the date of this current report.”
Rigel Pharmaceuticals Inc Form 8-K, filed October 11, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • Senior Advisor, Legal & Corporate Affairs

    Analyst

    Source not stated

    Current
  • Rigel Pharmaceuticals Inc (RIGL)

    General Counsel

    Proxy statement

    Start not stated–2022-10-11

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 Rigel Pharmaceuticals Inc (RIGL) $524,890 $1,194,583
2019 Rigel Pharmaceuticals Inc (RIGL) $514,598 $1,181,962
2018 Rigel Pharmaceuticals Inc (RIGL) $504,508 $1,770,828

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.